Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Leo J. Schep, Robin J. Slaughter, J. Allister Vale, D. Michael G. Beasley & Paul Gee. (2011) The clinical toxicology of the designer “party pills” benzylpiperazine and trifluoromethylphenylpiperazine. Clinical Toxicology 49:3, pages 131-141.
Read now
Read now
Paul Gee, Tom Jerram & David Bowie. (2010) Multiorgan failure from 1-benzylpiperazine ingestion – legal high or lethal high?. Clinical Toxicology 48:3, pages 230-233.
Read now
Read now
Articles from other publishers (50)
Citlaly Gutiérrez-Rodelo, Aurora Ochoa-López, José Luis Balderas-López, Adelfo Reyes-Ramírez, Cesar Millán-Pacheco, Fernando Favela-Rosales & Andrés Navarrete. (2023) “Eritadenine as a regulator of anxiety Disorders: An experimental and docking Approach”. Neuroscience Letters 813, pages 137413.
Crossref
Crossref
Ana Y. Simão, Mónica Antunes, Emanuel Cabral, Patrik Oliveira, Luana M. Rosendo, Ana Teresa Brinca, Estefânia Alves, Hernâni Marques, Tiago Rosado, Luís A. Passarinha, Maristela Andraus, Mário Barroso & Eugenia Gallardo. (2022) An Update on the Implications of New Psychoactive Substances in Public Health. International Journal of Environmental Research and Public Health 19:8, pages 4869.
Crossref
Crossref
Christopher Yates & Piotr M. Kabata. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
181
202
.
Paul Gee & Leo J. Schep. 2022. Novel Psychoactive Substances. Novel Psychoactive Substances
301
332
.
Deborah Rudin, Matthias E. Liechti & Dino Luethi. (2021) Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. Experimental Neurology 343, pages 113778.
Crossref
Crossref
Raquel G. Rocha, Isabella C.O.F. Silva, Luciano C. Arantes, Jéssica S. Stefano, Camila D. Lima, Larissa M.A. Melo, Rodrigo A.A. Munoz, Wallans T.P. dos Santos & Eduardo M. Richter. (2021) Simple and rapid electrochemical detection of 1-benzylpiperazine on carbon screen-printed electrode. Microchemical Journal 167, pages 106282.
Crossref
Crossref
Dino Luethi & Matthias E. Liechti. (2020) Designer drugs: mechanism of action and adverse effects. Archives of Toxicology 94:4, pages 1085-1133.
Crossref
Crossref
Caroline Souto, Gabriela Göethel, Caroline Portela Peruzzi, Larissa Vivan Cestonaro, Ingrid Garcia, Daiana Silva Ávila, Vera Eifler‐Lima, Helena Carmo, Maria de Lurdes Bastos, Solange C. Garcia & Marcelo Dutra Arbo. (2019)
Piperazine designer drugs elicit toxicity in the alternative in vivo model
Caenorhabditis elegans
. Journal of Applied Toxicology 40:3, pages 363-372.
Crossref
Crossref
Carlo Alessandro Locatelli, Davide Lonati & Valeria Margherita Petrolini. 2020. Brain and Heart Dynamics. Brain and Heart Dynamics
1
27
.
Carlo Alessandro Locatelli, Davide Lonati & Valeria Margherita Petrolini. 2020. Brain and Heart Dynamics. Brain and Heart Dynamics
843
868
.
M. Rosaria Varì, Simona Pichini, Raffaele Giorgetti & Francesco P. Busardò. (2018) New psychoactive substances—Synthetic stimulants. WIREs Forensic Science 1:2.
Crossref
Crossref
Ryan Graddy, Megan E. Buresh & Darius A. Rastegar. (2018) New and Emerging Illicit Psychoactive Substances. Medical Clinics of North America 102:4, pages 697-714.
Crossref
Crossref
Laura Hondebrink, Anne Zwartsen & Remco H.S. Westerink. (2018) Effect fingerprinting of new psychoactive substances (NPS): What can we learn from in vitro data?. Pharmacology & Therapeutics 182, pages 193-224.
Crossref
Crossref
Diana Dias da Silva, Maria João Silva, Patrícia Moreira, Maria João Martins, Maria João Valente, Félix Carvalho, Maria de Lourdes Bastos & Helena Carmo. (2016) In vitro hepatotoxicity of ‘Legal X’: the combination of 1-benzylpiperazine (BZP) and 1-(m-trifluoromethylphenyl)piperazine (TFMPP) triggers oxidative stress, mitochondrial impairment and apoptosis. Archives of Toxicology 91:3, pages 1413-1430.
Crossref
Crossref
Anne Campbell, Nina O Neill & Kathryn Higgins. (2017) Health and Social Care workers’ perceptions of NPS use in Northern Ireland. International Journal of Drug Policy 40, pages 93-101.
Crossref
Crossref
Marcelo Dutra Arbo, Simone Melega, Regina Stöber, Markus Schug, Eugen Rempel, Jörg Rahnenführer, Patricio Godoy, Raymond Reif, Cristina Cadenas, Maria de Lourdes Bastos, Helena Carmo & Jan G. Hengstler. (2016) Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis. Archives of Toxicology 90:12, pages 3045-3060.
Crossref
Crossref
D.P. Katz, J. Deruiter, D. Bhattacharya, M. Ahuja, S. Bhattacharya, C.R. Clark, V. Suppiramaniam & M. Dhanasekaran. (2016) Benzylpiperazine: “A messy drug”. Drug and Alcohol Dependence 164, pages 1-7.
Crossref
Crossref
Karolina Persona, Anna Polus, Joanna Góralska, Anna Gruca, Aldona Dembińska-Kieć & Wojciech Piekoszewski. (2016) An In Vitro Study of the Neurotoxic Effects of N-Benzylpiperazine: A Designer Drug of Abuse. Neurotoxicity Research 29:4, pages 558-568.
Crossref
Crossref
Julia Dinger, Markus R. Meyer & Hans H. Maurer. (2014) In vitro cytochrome P450 inhibition potential of methylenedioxy-derived designer drugs studied with a two-cocktail approach. Archives of Toxicology 90:2, pages 305-318.
Crossref
Crossref
Hege M. Krabseth, Silja S. Tuv, Maren Cecilie Strand, Ritva A. Karinen, Elisabeth Wiik, Merete S. Vevelstad, Andreas Austgulen Westin, Elisabeth L. Øiestad & Vigdis Vindenes. (2016) Nye psykoaktive stoffer. Tidsskrift for Den norske legeforening 136:8, pages 714-717.
Crossref
Crossref
M. D. Arbo, R. Silva, D. J. Barbosa, D. Dias da Silva, S. P. Silva, J. P. Teixeira, M. L. Bastos & H. Carmo. (2016)
In vitro
neurotoxicity evaluation of piperazine designer drugs in differentiated human neuroblastoma SH-SY5Y cells
. Journal of Applied Toxicology 36:1, pages 121-130.
Crossref
Crossref
Markus R. Meyer, Anna Holderbaum, Pierce Kavanagh & Hans H. Maurer. (2015) Low resolution and high resolution MS for studies on the metabolism and toxicological detection of the new psychoactive substance methoxypiperamide (MeOP). Journal of Mass Spectrometry 50:10, pages 1163-1174.
Crossref
Crossref
Rawan Albadareen, Stephen ThorntonArezou Heshmati, Roy Gerona & Jennifer Lowry. (2015) Unusually Prolonged Presentation of Designer Drug Encephalopathy Responsive to Steroids. Pediatrics 136:1, pages e246-e248.
Crossref
Crossref
Brian P. Kersten & Megan E. McLaughlin. (2014) Toxicology and Management of Novel Psychoactive Drugs. Journal of Pharmacy Practice 28:1, pages 50-65.
Crossref
Crossref
Christopher D Smith & Stefanie Robert. (2014) ‘Designer drugs’: update on the management of novel psychoactive substance misuse in the acute care setting. Clinical Medicine 14:4, pages 409-415.
Crossref
Crossref
Marcelo Dutra Arbo, Renata Silva, Daniel José Barbosa, Diana Dias da Silva, Luciana Grazziotin Rossato, Maria de Lourdes Bastos & Helena Carmo. (2014) Piperazine designer drugs induce toxicity in cardiomyoblast h9c2 cells through mitochondrial impairment. Toxicology Letters 229:1, pages 178-189.
Crossref
Crossref
Luca Zamengo, Giampietro Frison, Chiara Bettin & Rocco Sciarrone. (2014) Understanding the risks associated with the use of new psychoactive substances (NPS): High variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products. Toxicology Letters 229:1, pages 220-228.
Crossref
Crossref
Megan E. Musselman & Jeremy P. Hampton. (2014)
“
Not for Human Consumption”: A Review of Emerging Designer Drugs
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:7, pages 745-757.
Crossref
Crossref
Michael E. Nelson, Sean M. Bryant & Steven E. Aks. (2014) Emerging drugs of abuse. Disease-a-Month 60:3, pages 110-132.
Crossref
Crossref
Linda D. Simmler, Anna Rickli, York Schramm, Marius C. Hoener & Matthias E. Liechti. (2014) Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochemical Pharmacology 88:2, pages 237-244.
Crossref
Crossref
Nicolas Hohmann, Gerd Mikus & David Czock. (2014) Effects and Risks Associated with Novel Psychoactive Substances. Deutsches Ärzteblatt international.
Crossref
Crossref
Michael E. Nelson, Sean M. Bryant & Steven E. Aks. (2014) Emerging Drugs of Abuse. Emergency Medicine Clinics of North America 32:1, pages 1-28.
Crossref
Crossref
Márcia Sá Monteiro, Maria de Lourdes Bastos, Paula Guedes de Pinho & Márcia Carvalho. (2013) Update on 1-benzylpiperazine (BZP) party pills. Archives of Toxicology 87:6, pages 929-947.
Crossref
Crossref
Karolina Persona, Julien Verget, Agnieszka Przybyłowicz, Ewa Gomółka & Wojciech Piekoszewski. (2013) Determination of N-benzylpiperazine in human plasma using derivatization-free liquid–liquid extraction and gas chromatography mass spectrometry. Analytical Methods 5:18, pages 4805.
Crossref
Crossref
Paul Gee & Leo Schep. 2013. Novel Psychoactive Substances. Novel Psychoactive Substances
179
209
.
Kevin Woodward & Kevin WoodwardK. N. Woodward. 2012. Toxicological Effects of Veterinary Medicinal Products in Humans. Toxicological Effects of Veterinary Medicinal Products in Humans
95
154
.
M.D. Arbo, M.L. Bastos & H.F. Carmo. (2012) Piperazine compounds as drugs of abuse. Drug and Alcohol Dependence 122:3, pages 174-185.
Crossref
Crossref
Donald G. BarcelouxBrandon Wills & Timothy Erickson. 2012. Medical Toxicology of Drug Abuse. Medical Toxicology of Drug Abuse
156
192
.
LINDA BERNEY-MEYER, TRACEY PUTT, JOHN SCHOLLUM & ROBERT WALKER. (2012) Nephrotoxicity of recreational party drugs. Nephrology 17:2, pages 99-103.
Crossref
Crossref
M. Perrin, Y. Lecompte, O. Roussel, R. Le Boisselier, J. Bourgine & A. Coquerel. 2012. Traité De Toxicologie Médico-judiciaire. Traité De Toxicologie Médico-judiciaire
507
547
.
Leo J. Schep, Robin J. Slaughter, Wayne A. Temple & Paul Gee. (2011) Comments on BZP and New Zealand's alternative approach to prohibition. Drug Testing and Analysis 4:1, pages 57-57.
Crossref
Crossref
. (2011) Response to the letter: Comments on BZP and New Zealand's alternative approach to prohibition. Drug Testing and Analysis 4:1, pages 58-58.
Crossref
Crossref
Joanne C. Lin, Reem K. Jan, Rob R. Kydd & Bruce R. Russell. (2011) Subjective effects in humans following administration of party pill drugs BZP and TFMPP alone and in combination. Drug Testing and Analysis 3:9, pages 582-585.
Crossref
Crossref
Simon Elliott. (2011) Current awareness of piperazines: pharmacology and toxicology. Drug Testing and Analysis 3:7-8, pages 430-438.
Crossref
Crossref
Joanne C. Lin, Reem K. Jan, HeeSeung Lee, Maree-Ann Jensen, Rob R. Kydd & Bruce R. Russell. (2010) Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology 214:3, pages 761-768.
Crossref
Crossref
John Tully, Brian Hallahan & Colm McDonald. (2014) Benzylpiperazine-induced acute delirium in a patient with schizophrenia and an incidental temporal meningioma. Irish Journal of Psychological Medicine 28:1, pages S14-S16.
Crossref
Crossref
Martin M. Schmidt, Akhilesh Sharma, Fabrizio Schifano & Charlotte Feinmann. (2011) “Legal highs” on the net—Evaluation of UK-based Websites, products and product information. Forensic Science International 206:1-3, pages 92-97.
Crossref
Crossref
Bruce M.Z. Cohen & Rachael Butler. (2011) BZP-party pills: A review of research on benzylpiperazine as a recreational drug. International Journal of Drug Policy 22:2, pages 95-101.
Crossref
Crossref
Jayendra K. Patel, Sarah Langenfeld & Eileen Wong. 2011. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
53
70
.
M. Galicia, S. Nogué, E. Sanjurjo & O. Miró. (2010) Consultas urgentes derivadas del consumo de éxtasis (3,4-metilenodioximetanfetamina) y derivados anfetamínicos: perfil epidemiológico, clínico y evolutivo. Revista Clínica Española 210:8, pages 371-378.
Crossref
Crossref